New ALS drug trial seeks safer treatment, not a cure
NCT ID NCT05633459
First seen May 15, 2026 · Last updated May 15, 2026
Summary
This early-stage study tests the safety of a new drug called QRL-201 in 69 people with ALS, a nerve disease that weakens muscles. Participants receive either the drug or a placebo to check for side effects. The goal is to see if QRL-201 is safe enough for further testing, not to cure the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHUM - Hopital Notre-Dame
Montreal, Quebec, H2L 4M1, Canada
-
Charité Research Organisation
Berlin, 10117, Germany
-
Deutsches Zentrum für Neurodegenerative Erkrankungen e. V. (DZNE)
Bonn, North Rhine-Westphalia, 53127, Germany
-
Kings College Hospital NHS Foundation Trust
London, SE5 9RS, United Kingdom
-
Montreal Neurological Institute-Hospital
Montreal, Quebec, H3A 2B4, Canada
-
National Hospital for Neurology and Neurosurgery
London, WC1N 3BG, United Kingdom
-
St James's Hospital
Dublin, D08 A978, Ireland
-
Sunnybrook Health Science Centre
Toronto, Ontario, M4N 3M5, Canada
-
The University of Sheffield, Royal Hallamshire Hospital
Sheffield, United Kingdom, S10 2JF, United Kingdom
-
Universitair Medisch Centrum Utrecht
Utrecht, Netherlands
-
Universitaire Ziekenhuizen Leuven (UZ Leuven)
Leuven, B-3000, Belgium
-
University Hospital Schleswig-Holstein (UKSH) Campus Lübeck, Department for Neurology/ Precision Neurology
Lübeck, Germany
-
University of Alberta
Edmonton, Alberta, T6G 2G3, Canada
-
University of Calgary
Calgary, Alberta, T2N 1N4, Canada
-
Universitätsklinikum Ulm
Ulm, 89081, Germany
Conditions
Explore the condition pages connected to this study.